Physicians can use TeloTrack CHD to assess risk of coronary heart disease (CHD) based on telomere length (TL). Telomere length associates with risk of heart disease independent of conventional vascular risk factors.1,2 TeloTrack CHD measures Average Telomere Length (ATL) from a whole blood sample.
Telomeres are the dynamic protective caps on the end of DNA strands that can change over time.3 TeloTrack CHD is a lab developed test that helps identify risk for CHD in patients ≥ 45 years of age who have no prior history of CHD.
The Nobel Prize in Medicine for breakthrough discoveries in Telomere Biology was awarded in 2009 to one of the founders of the company now providing TeloYears.4 No other DNA test has had more prestigious scientific research supporting its development.
TeloTrack CHD is a risk assessment tool that doctors can use to monitor a patient’s risk of CHD while helping them engage in improved lifestyle management. TeloTrack CHD measures ATL from a whole blood sample. Telomeres are the dynamic protective caps on the end of DNA strands that can change over time.4 TeloTrack CHD is a lab developed test that helps identify risk for CHD in patients ≥45 years of age who have no prior history of coronary heart disease.
From a simple finger stick, TeloTrack CHD measures ATL from just a few drops of blood.
DNA is isolated from a whole blood (leukocyte) sample collected from a finger stick and analyzed using a validated quantitative polymerase chain reaction (qPCR) method to determine the patient’s ATL. ATL is expressed numerically as a T/S ratio, a common unit of measure in published literature that expresses ATL relative to the known length of two single copy genes present in the genome.5
The patient’s ATL result is adjusted for age and gender and categorized into one of three tertiles corresponding to long, medium, or short telomere length. This ATL tertile is calculated using a statistical model derived from the measurement of ATL on a representative sample of over 10,000 individuals (age 35 to 80 years old) in the U.S. general population. Consistent with ACC/AHA guideline conventions, the patient’s level of CHD risk is reported as low, intermediate, or high risk based on ATL tertile (long, medium, or short respectively), which has been shown to correspond with the level of CHD risk independent of conventional vascular risk factors.2
Ordering TeloTrack CHD for your patients takes four simple steps:
* use your credit card or request an invoice